目的 探究蓝芩口服液联合左氧氟沙星序贯疗法治疗社区获得性肺炎患者的临床疗效。方法 回顾性分析铜陵市人民医院2022年1月—2025年7月收治的100例社区获得性肺炎患者的临床资料，根据治疗方案的不同分为对照组和治疗组，其中对照组49例，治疗组51例。对照组采用左氧氟沙星序贯治疗方案，给予左氧氟沙星注射液静脉滴注，每次剂量为0.5 g，每日1次，连续静脉滴注3 d；待患者体温恢复正常、临床症状明显缓解后，转为口服盐酸左氧氟沙星片，每次0.2 g，每日2次。治疗组在对照组治疗方案的基础上联合口服蓝芩口服液，每次20 mL，每日3次。两组连续治疗14 d。观察两组患者的临床治疗效果、症状消失时间，比较实验室检测指标（血常规、炎症标志物指标）、肺部影像学表现。结果 治疗组的总有效率是96.08%显著高于对照组的81.63%，（P＜0.05）。治疗后，治疗组发热、咳痰、胸闷、喘息及胸痛消失时间均短于对照组（P＜0.05）。治疗后，两组白细胞计数（WBC）、中性粒细胞比例（NEUT%）均较治疗前明显下降（P＜0.05）；且治疗后，治疗组WBC、NEUT%水平均显著低于对照组，差异均有统计学意义（P＜0.05）。治疗后，两组患者C反应蛋白（CRP）、降钙素原（PCT）、血清淀粉样蛋白A（SAA）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平均较治疗前显著降低（P＜0.05）；治疗后，治疗组CRP、PCT、SAA、TNF-α、IL-6水平低于对照组（P＜0.05）。治疗后，治疗组肺部炎症总吸收率（90.20%）显著高于对照组（73.47%），组间差异有统计学意义（P＜0.05）。结论 蓝芩口服液联合左氧氟沙星序贯疗法治疗社区获得性肺炎临床治疗效果得到明显提升，加快患者临床症状缓解及肺部炎症吸收，值得临床推广应用。

Objective To investigate the clinical efficacy of Lanqin Oral Liquid combined with levofloxacin sequential therapy in treatment of community acquired pneumonia. Methods A retrospective analysis was conducted on the clinical data of 100 patients with community acquired pneumonia admitted to Tongling People’s Hospital from January 2022 to July 2025. These patients were divided into control group and treatment group based on different treatment plans, there were 49 cases in control group and 51 cases in treatment group. The control group received the sequential treatment regimen of levofloxacin, with Levofloxacin Injection administered by intravenous drip, at a dose of 0.5 g each time, once daily, for a continuous 3 d intravenous infusion. Once the patients’ body temperature returned to normal and the clinical symptoms significantly improved, the treatment was switched to oral Levofloxacin Hydrochloride Tablets, at a dose of 0.2 g each time, twice daily. The treatment group, in addition to the treatment regimen of control group, also took oral Lianqin Oral Liquid, 20 mL each time, three times daily. Both groups received continuous treatment for 14 d. The clinical treatment effects and symptom disappearance times of two groups were observed, and the laboratory test indicators (blood routine, inflammatory marker indicators) and pulmonary imaging manifestations were compared. Results The total effective rate of treatment group was 96.08%, significantly higher than that of control group (81.63%) (P < 0.05). After treatment, the disappearance time of fever, expectoration, chest tightness, wheezing and chest pain in treatment group was shorter than that in control group (P < 0.05). After treatment, the white blood cell count (WBC) and the proportion of neutrophils (NEUT%) in both groups decreased significantly compared with those before treatment (P < 0.05). After treatment, the WBC and NEUT% levels in treatment group were significantly lower than those in control group, and differences were statistically significant (P < 0.05). After treatment, the levels of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in both groups were significantly lower than those before treatment (P < 0.05). After treatment, the levels of CRP, PCT, SAA, TNF-α, and IL-6 in treatment group were lower than those in the control group (P < 0.05). After treatment, the total absorption rate of pulmonary inflammation in treatment group (90.20%) was significantly higher than that in control group (73.47%), and the difference was statistically significant (P < 0.05). Conclusion Lanqin Oral Liquid combined with levofloxacin sequential therapy in treatment of community acquired pneumonia can significantly improve clinical efficacy, accelerate symptom resolution and pulmonary inflammation absorption, which is warranting clinical promotion and application.

R974

安徽省自然科学基金项目（2308085MH251）